News
KLRS
6.59
+12.27%
0.72
This Dick's Sporting Goods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga · 16h ago
Morgan Stanley Initiates Coverage On Kalaris Therapeutics with Overweight Rating, Announces Price Target of $14
Benzinga · 19h ago
Kalaris Therapeutics initiated with an Overweight at Morgan Stanley
TipRanks · 19h ago
U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services
Reuters · 20h ago
Kalaris Therapeutics Launches Up To $100M At-The-Market Stock Offering Agreement With TD Cowen
Benzinga · 3d ago
KALARIS THERAPEUTICS INC - MAY SELL COMMON STOCK UP TO $100 MLN THROUGH OR TO TD COWEN - SEC FILING
Reuters · 3d ago
Weekly Report: what happened at KLRS last week (0406-0410)?
Weekly Report · 3d ago
Kalaris Therapeutics Announces CFO Resignation, Finance Leadership Shift
TipRanks · 6d ago
BRIEF-Kalaris Therapeutics Inc - Matthew Gall Resigns As CFO Effective April 14, 2026 - SEC Filing
Reuters · 6d ago
Kalaris Therapeutics CFO Matthew Gall Resigns, Effective April 14
Benzinga · 6d ago
Kalaris CFO Matthew Gall resigns; Chief Accounting Officer Brett Hagen named principal financial officer
Reuters · 6d ago
Weekly Report: what happened at KLRS last week (0330-0403)?
Weekly Report · 04/06 10:35
KALARIS THERAPEUTICS INC - MAY OFFER UP TO $350 MLN IN SECURITIES - SEC FILING
Reuters · 04/03 20:20
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 03/31 17:30
Weekly Report: what happened at KLRS last week (0323-0327)?
Weekly Report · 03/30 10:35
Top Kalaris Therapeutics Executive Quietly Unloads Company Shares
TipRanks · 03/24 02:02
Kalaris Therapeutics Chief Accounting Officer Brett Hagen disposes of USD 12,869 of common shares
Reuters · 03/23 20:06
Weekly Report: what happened at KLRS last week (0316-0320)?
Weekly Report · 03/23 10:31
Kalaris Therapeutics, Inc. GAAP EPS of -$2.85
Seeking Alpha · 03/17 19:50
More
Webull provides a variety of real-time KLRS stock news. You can receive the latest news about Kalaris Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).